The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers
Completed
The Catholic University of Korea
Phase 1
An open-label, multiple-dose, single-arm, phase 1 study to evaluate the drug-drug interaction
and safety of Lafutidine and Irsogladine maleate in healthy adult volunteers
The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers
Completed
Boryung Pharmaceutical Co., Ltd
Phase 1
An open-label, multiple-dose, single-arm, phase 1 study to evaluate the drug-drug interaction
and safety of Lafutidine and Irsogladine maleate in healthy adult volunteers
A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet
Completed
Boryung Pharmaceutical Co., Ltd
Phase 1
An Open-Label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics
of BRI-1501 Tablet and Coadministration of Lafutidine and Irsogladine maleate as Individual
Tablets in Healthy Adult Volunteers
Therapeutic Effect of Isoladine Maleate on Small Intestinal Mucosal Injury Associated With NSAIDS in Population
Not yet recruiting
Lee's Pharmaceutical Limited
Phase 4
All patients who met the inclusion criteria and agreed to participate in the study underwent
baseline capsule endoscopy. Patients with intestinal mucosal injury detected during the
initial capsule endoscopy were randomly divided into isoladin maleate group or magnesium
aluminum carbonate control group using computer-generated random numbers. Patients in the
isoladine maleate group received 4 mg isoladine maleate (Gesellon, Japan) every morning for 4
weeks (or 8 weeks, duration to be determined); Magnesium aluminum carbonate control group
received 1 g magnesium aluminum carbonate every morning, afternoon and evening for 4 weeks
(or 8 weeks, course to be determined). After treatment, capsule endoscopy was performed again
to evaluate the healing of intestinal mucosa.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
